8-K: Align Technology Exceeds Q3 Revenue Outlook

Align Technology reported third-quarter 2025 revenues of $995.7 million, surpassing its guidance, driven by strong international Clear Aligner volume growth, particularly in teens and kids.

Summary

• Total revenues for Q3'25 reached $995.7 million, marking a 1.8% year-over-year increase and a 1.7% sequential decrease, but exceeded the company's outlook range of $965 million to $985 million.
• Clear Aligner revenues were $805.8 million, up 2.4% year-over-year and 0.1% sequentially, with volume increasing 4.9% year-over-year and 0.5% sequentially to 647.8 thousand cases.
• Clear Aligner volume for teens and kids showed significant growth, up 8.3% year-over-year and 14.7% sequentially, reaching 256.0 thousand cases.
• Imaging Systems and CAD/CAM Services revenues were $189.9 million, down 0.6% year-over-year and 8.6% sequentially, as expected due to capital equipment seasonality.
• GAAP operating income was $96.3 million, resulting in a GAAP operating margin of 9.7%, which was significantly impacted by $88.3 million in restructuring, impairment, and accelerated depreciation charges.
• Non-GAAP operating income was $237.8 million, with a non-GAAP operating margin of 23.9%, exceeding the company's outlook of approximately 22%.
• GAAP diluted net income per share was $0.78, while non-GAAP diluted net income per share was $2.61.
• Cash and cash equivalents stood at $1,004.6 million as of September 30, 2025, up from $901.2 million in Q2'25.
• Repurchased approximately 0.5 million shares of common stock at an average price of $136.77 per share during Q3'25.

Sentiment

Score: 7

Explanation: The sentiment is positive due to exceeding revenue and non-GAAP operating margin guidance, strong international growth, and strategic product innovations. However, significant GAAP profitability impacts from restructuring charges and mixed North American market activity temper the overall score.

Positives

• Q3'25 total revenues of $995.7 million exceeded the company's guidance range of $965 million to $985 million.
• Clear Aligner volume increased 4.9% year-over-year, driven by strong performance in EMEA, APAC, and Latin America regions.
• Clear Aligner volume for teens and kids grew significantly by 8.3% year-over-year and 14.7% sequentially, reflecting increased doctor submitters and adoption of Invisalign First.
• Non-GAAP operating margin of 23.9% was above the company's outlook of approximately 22%.
• Cash and cash equivalents increased to over $1 billion, demonstrating strong liquidity.
• Introduced ClinCheck Live Plan, automating initial treatment plan generation within 15 minutes, significantly reducing the planning cycle.
• Announced new product innovations for iTero Digital Solutions to enhance dental consultations and Invisalign treatment conversion.
• President and CEO Joe Hogan personally purchased approximately $1 million worth of Align common stock, signaling management confidence.
• Filed patent infringement lawsuits and a Section 337 complaint against Angelalign Technology, Inc., indicating proactive intellectual property defense.

Negatives

• GAAP operating income and operating margin were significantly lower year-over-year and sequentially due to $88.3 million in restructuring, impairment, and accelerated depreciation charges.
• GAAP diluted net income per share of $0.78 was substantially lower compared to $1.72 in Q2'25 and $1.55 in Q3'24.
• Imaging Systems and CAD/CAM Services revenues were down 0.6% year-over-year and 8.6% sequentially, although this was expected due to capital equipment seasonality.
• Activity in the orthodontic and dental markets remains mixed, particularly in North America.

Risks

• Macroeconomic conditions, including inflation, currency exchange rate fluctuations, higher interest rates, market volatility, supply chain challenges, customs duties, and geopolitical tensions.
• Customer and consumer purchasing behavior changes due to economic conditions, employment levels, and discretionary income.
• Threats or actual tariffs and retaliatory actions impacting products and sales.
• Variations in geographic, channel, and product mix, including shifts to lower-priced products.
• Competition from existing and new competitors.
• Declines in, or slowing growth of, sales of clear aligners and intraoral scanners.
• Geopolitical ramifications of military conflicts and tensions affecting operations.
• Ability to implement and realize anticipated benefits from business realignment and workforce reductions.
• Development and release of new products or enhancements not proceeding as anticipated, or containing bugs/defects.
• Timing, availability, and cost of raw materials, components, and supply chain disruptions.
• Unexpected or rapid changes in market growth or decline.
• Rapidly evolving and groundbreaking advances altering the dental industry.
• Ability to protect intellectual property rights.
• Continued compliance with regulatory requirements.
• Willingness and ability of customers to maintain and/or increase product utilization.
• Ability to sustain or increase profitability or revenue growth while controlling expenses.
• Impact of excess or constrained capacity at manufacturing facilities and pressure on internal systems.
• Compromise of systems or networks, including customer and/or patient data.
• Timing of case submissions from doctor customers and increased manufacturing costs per case.
• Loss of key personnel, labor shortages, or work stoppages.

Future Outlook

For Q4'25, worldwide revenues are expected to be in the range of $1,025 million to $1,045 million, with Clear Aligner volume and average selling price, as well as Systems and Services revenues, anticipated to be up sequentially. GAAP gross margin is projected at 65.5% to 66.0% and non-GAAP gross margin at approximately 71.0%. GAAP operating margin is expected to be 15.3% to 15.8%, with non-GAAP operating margin around 26.0%. For fiscal year 2025, Clear Aligner volume growth is projected to be mid-single digits, and revenue growth is expected to be flat to slightly up from 2024. GAAP operating margin is estimated around 13.6% to 13.8%, impacted by approximately $145 million to $155 million in non-cash charges, while non-GAAP operating margin is expected to be slightly above 22.5%. Capital expenditures for fiscal 2025 are estimated at approximately $100 million, primarily for technology upgrades. Restructuring actions are nearing completion and are expected to improve GAAP and non-GAAP operating margins by at least 100 basis points year-over-year.

Management Comments

• "I am pleased to report third quarter revenues, Clear Aligner volumes, and non-GAAP operating margins, all above our outlook."
• "Our Q3 results reflect year-over-year growth in Clear Aligner volumes, driven primarily by the EMEA, APAC, and Latin America regions, as well as strong sequential growth from the APAC and Latin America regions, driven primarily by the teens and kids' category."
• "Our Q3 Systems and Services revenues were down year-over-year and sequentially, as expected, given Q3 capital equipment seasonality."
• "While activity in the orthodontic and dental markets remains mixed, especially in North America, the initiatives we're taking to drive consumer demand and patient conversion, including working with our DSO partners, are delivering results and we will continue to focus on execution of these go-to-market programs."
• "The breadth and depth of our global business and product portfolio, and consumer preference for the Invisalign brand, are unique advantages that provide balance in a dynamic global market."
• "The year-over-year Clear Aligner volume growth rate improved from Q2 to Q3, for all our top 10 country markets, except for Canada."

Industry Context

The orthodontic and dental markets are experiencing mixed activity, particularly in North America. Despite these challenges, Align Technology leverages its global business, diverse product portfolio (Invisalign, iTero, exocad), and strong consumer preference for the Invisalign brand to maintain balance in a dynamic global market. The company is also actively defending its intellectual property against competitors like Angelalign Technology, Inc., indicating a competitive landscape.

Comparison to Industry Standards

• The filing notes that activity in the orthodontic and dental markets remains mixed, especially in North America, without providing specific comparable company performance or industry benchmarks.
• Align Technology highlights its global business, product portfolio, and consumer preference for the Invisalign brand as unique advantages in a dynamic global market, suggesting a strong competitive position despite broader market conditions.

Legal Proceedings

• On September 23, 2025, filed a complaint under Section 337 of the Tariff Act with the U.S. International Trade Commission against Angelalign Technology, Inc., alleging unauthorized importation and sale of clear aligners infringing Align's patents.
• On August 18, 2025, filed patent infringement lawsuits against Angelalign Technology, Inc., a Shanghai-based manufacturer of clear aligners.

Related Party Transactions

• On August 1, 2025, President and CEO Joe Hogan personally purchased approximately $1 million worth of Align common stock.

Stakeholder Impact

• Shareholders: Positive from exceeding guidance and ongoing share repurchase program, but GAAP EPS was significantly reduced by restructuring charges. CEO's stock purchase signals confidence.
• Employees: Impacted by restructuring actions, which include headcount reductions and post-employment benefits, aimed at increasing efficiency.
• Customers (Doctors): Benefit from new product innovations like ClinCheck Live Plan and iTero Digital Solutions, and educational events, enhancing treatment planning and practice efficiency. UK VAT adjustments aim to maintain consistent pricing.
• Competitors: Angelalign Technology, Inc. is facing legal challenges from Align Technology regarding patent infringement, potentially impacting its market position.

Next Steps

• Host a conference call on October 29, 2025, to review Q3'25 financial results and discuss future operating trends and business outlook.
• Continue to focus on execution of go-to-market programs to drive consumer demand and patient conversion.
• Complete the $200.0 million open market repurchase plan for common stock by January 2026.
• Near completion of restructuring actions intended to sharpen operational focus, reduce ongoing costs, and enhance capital efficiency, with expected improvements in operating margins.
• Invest approximately $100 million in capital expenditures for fiscal 2025, primarily for technology upgrades.

Key Dates

Recommendation

Align Technology's Q3'25 results, particularly exceeding revenue and non-GAAP operating margin guidance, demonstrate underlying business strength despite a mixed market and significant one-time GAAP charges from restructuring. Strong growth in Clear Aligner volume, especially in the teens and kids segment and international markets, coupled with strategic product innovations (ClinCheck Live Plan, iTero Digital Solutions) and proactive intellectual property defense, positions the company for continued leadership. The CEO's personal stock purchase further reinforces confidence. While GAAP profitability was temporarily impacted, the positive non-GAAP performance and optimistic Q4 and FY2025 outlook, including expected margin improvements from restructuring, suggest a favorable long-term trajectory for investors.

Keywords

Align Technology, ALGN, Invisalign, Clear Aligners, iTero, exocad, Dental Technology, Orthodontics, Financial Results, Q3 2025, Earnings, Medical Device, Digital Dentistry, Patent Infringement, Restructuring